The grant is one of the Novo Nordisk Foundation’s largest and will fund a 12-year research collaboration to construct a quantum computer dedicated to the life sciences.

The Swiss company is evaluating “all available options” following the ruling, which could lead to the launch of copycat versions of its MS drug Gilenya.

The roughly 200,000-square-foot facility will house about 400 employees and more than double the size of the drugmaker’s presence in San Francisco.

Safety concerns had derailed a slate of studies involving the drug, called islatravir, last fall. A partial FDA hold remains on any study using a higher dose.

Rocket is acquiring Renovacor at a roughly 75% discount to its public debut price last year, when it became one of dozens of biotechs to merge with a blank check company, or SPAC. 

When the company debuted in March, it announced plans to hire 200 employees over two years. Now, it’s laid off nearly half its staff in a year when the biotech sector has experienced a sharp market downturn.

The FDA's clearances of Zynteglo and Skysona are a boost to Bluebird, and could help lift the research field after a series of setbacks. But selling the high-priced therapies will be a challenge.

The French company, still aiming to rebound from a Phase 3 study failure two years ago, will pay about $41 million for Versantis and its experimental liver disease drugs. 

The planned transaction will further unwind the respiratory disease company’s relationship with GSK, which dates back two decades.

Elevate pharma product development and marketing through collaboration with physician experts

The therapy, called Skysona and cleared to treat cerebral adrenoleukodystrophy, is the product of more than a decade of work by Bluebird. It will cost $3 million.

If authorized by the European Commission, the companies’ antibody medicine would become the first cleared for broad use in newborns and infants.